Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascelia Pharma AB ( (SE:ACE) ) has provided an update.
Ascelia Pharma is positioning itself in the orphan oncology space with imaging and chemotherapy products targeting underserved patient groups. The company’s lead asset, Orviglance, addresses an estimated USD 800 million annual market for safer liver imaging in patients with severe renal impairment, while Oncoral advances as an oral chemotherapy option.
The 2025 annual report highlights a pivotal 2026, with the U.S. Food and Drug Administration formally accepting the New Drug Application for Orviglance and a potential approval expected in 2026 alongside a planned commercial partner for the U.S. launch. Successful approval and partnering would mark a major operational shift towards commercialization, potentially strengthening Ascelia Pharma’s market position and creating new value for shareholders in a sizable niche market.
The most recent analyst rating on (SE:ACE) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Ascelia Pharma AB stock, see the SE:ACE Stock Forecast page.
More about Ascelia Pharma AB
Ascelia Pharma AB is a specialty pharmaceutical company focused on orphan oncology treatments. Its pipeline includes Orviglance, a novel contrast agent for visualizing liver lesions in patients with severe kidney impairment, and Oncoral, a daily oral chemotherapy candidate preparing to enter Phase 2 development.
Average Trading Volume: 804,325
Technical Sentiment Signal: Sell
Current Market Cap: SEK367.3M
Find detailed analytics on ACE stock on TipRanks’ Stock Analysis page.